The U.S. Food and Drug Administration and the European Medicines Agency jointly issued principles for safe and responsible ...

Please provide your email address to receive an email when new articles are posted on . AIM-MASH AI Assist is the first AI drug development tool to be qualified by the FDA. The tool is designed to ...

BOSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- PathAI , a global leader in AI-powered pathology, today announced that the U.S. Food and Drug Administration (FDA) has qualified AIM-MASH AI Assist through ...

The FDA has qualified the first AI-based drug development tool to support metabolic dysfunction-associated steatohepatitis clinical trials. The cloud-based tool, AI-Based Histologic Measurement of ...

MPA on track to become the first NAM approved by the FDA for specificity testing PHILADELPHIA, Oct. 28, 2025 /PRNewswire/ -- Integral Molecular, a leader in antibody discovery and characterization, ...

PHILADELPHIA, Feb. 5, 2025 /PRNewswire/ -- Integral Molecular, a leader in antibody discovery technologies, is proud to announce that the FDA has accepted their Membrane Proteome Array™ (MPA) ...

The FDA has officially approved the first AI tool to help with liver disease drug trials, and it is designed to make reading liver biopsies for MASH faster, more consistent, and easier for ...

The MarketWatch News Department was not involved in the creation of this content. CHICAGO, Dec. 9, 2025 /PRNewswire/ -- Sibel Health, a leader in wearable biosensing and digital health, today ...

The U.S. Food and Drug Administration (FDA) has introduced “Elsa,” a generative AI tool designed to enhance the efficiency of its regulatory operations. Elsa's deployment comes nearly a month ahead of ...

The U.S. Food and Drug Administration (FDA) recently announced it plans to phase out animal testing in the development of monoclonal antibody therapies and other drugs and biological products “with ...